TY  - JOUR
AU  - Witzens-Harig, Mathias
AU  - Benner, Axel
AU  - McClanahan, Fabienne
AU  - Klemmer, Jennifer
AU  - Brandt, Julia
AU  - Brants, Elke
AU  - Rieger, Michael
AU  - Meissner, Julia
AU  - Hensel, Manfred
AU  - Neben, Kai
AU  - Dreger, Peter
AU  - Lengfelder, Eva
AU  - Schmidt-Wolf, Ingo
AU  - Krämer, Alwin
AU  - Ho, Anthony D
TI  - Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.
JO  - British journal of haematology
VL  - 171
IS  - 5
SN  - 0007-1048
CY  - Oxford [u.a.]
PB  - Wiley-Blackwell55962
M1  - DKFZ-2017-03825
SP  - 710 - 719
PY  - 2015
AB  - In the multicentre prospective randomized HD2002 trial, rituximab maintenance therapy (375 mg/m(2) every 3 months for 2 years) versus observation was evaluated for CD20(+) B-cell lymphoma. Out of 321 patients [161 randomized to the treatment group (TG), 160 to the observation group (OG)], 295 data sets were evaluable for statistical analysis. Estimated 5-year relapse-free survival (RFS) was 81
KW  - Antineoplastic Agents (NLM Chemicals)
KW  - Rituximab (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:26449739
DO  - DOI:10.1111/bjh.13652
UR  - https://inrepo02.dkfz.de/record/127803
ER  -